{
    "clinical_study": {
        "@rank": "46758", 
        "acronym": "BioFIND", 
        "arm_group": [
            {
                "arm_group_label": "Parkinson's Disease Subjects"
            }, 
            {
                "arm_group_label": "Healthy Control Subjects"
            }
        ], 
        "biospec_descr": {
            "textblock": "Cerebrospinal Fluid (CSF), whole blood, DNA, plasma"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This is an observational, multi-center study to assess clinical features and biologic\n      biomarkers in Parkinson's disease (PD) patients compared to healthy controls (HC). The\n      primary objective of this study is to discover clinical and biologic markers of PD for use\n      in clinical trials of disease-modifying therapies."
        }, 
        "brief_title": "Fox Investigation for New Discovery of Biomarkers", 
        "condition": "Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "detailed_description": {
            "textblock": "BioFIND is a two-year observational clinical study designed to discover and verify\n      biomarkers of Parkinson's disease (PD). BioFIND is collecting clinical data and\n      biospecimens, including blood and cerebrospinal fluid (CSF), in a population of 120\n      well-defined, moderately advanced PD subjects and 120 healthy controls.\n\n      BioFIND will follow standardized data acquisition protocols to ensure that tests and\n      assessments conducted at multiple sites can be pooled. Data and samples acquired from study\n      participants will enable the development of a comprehensive Parkinson's database and\n      biorepository, which will be available to the scientific community to conduct research on\n      novel PD biomarkers."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria (PD Subjects):\n\n          -  Subjects must have bradykinesia and rigidity.\n\n          -  Current or history of well documented resting tremor.\n\n          -  Unilateral onset or persistent asymmetry.\n\n          -  A well established response to dopaminergic agents including the presence of levodopa\n             induced dyskinesia for at least 3 years according to treating physician's judgment.\n\n          -  Subject has progressive PD of 5 to 18 years of duration from the onset of symptoms.\n\n          -  Male or female age of onset of PD 50 to 70 by history.  Current ages would range from\n             55 to 93 based on #5 and #6 requirements.\n\n          -  Ability to provide written informed consent in accordance with Good Clinical Practice\n             (GCP), International Conference on Harmonization (ICH), and local regulations.\n\n          -  Willing and able to comply with scheduled visits, required study procedures and\n             laboratory tests.\n\n        Exclusion Criteria (PD Subjects):\n\n          -  Family history of PD in first degree relatives.\n\n          -  Ashkenazi Jewish subject (defined as all 4 grandparents being Ashkenazi Jewish) will\n             be excluded because of the high likelihood of genetic forms of PD (LRRK2) and GBA),\n             unless these have been already excluded by genetic testing.\n\n          -  Has others serious neurological disorders (clinically significant stroke, brain\n             tumor, hydrocephalus, epilepsy, other neurodegenerative disorders, encephalitis,\n             repeated head trauma).\n\n          -  Has early severe autonomic involvement. Symptomatic orthostatic, hypotension or\n             urinary incontinence within one year of onset of disease symptom.\n\n          -  Current treatment with anticoagulants (e.g., Coumadin, heparin) that might preclude\n             safe completion of the lumbar puncture.\n\n          -  Condition that precludes the safe performance of routine lumbar puncture, such as\n             prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant\n             coagulopathy or thrombocytopenia.\n\n          -  Any other medical or psychiatric condition or lab abnormality, which in the opinion\n             of the investigator might preclude participation.\n\n          -  Use of investigational drugs or devices within 60 days prior to baseline (dietary\n             supplements taken outside of a clinical trial are not exclusionary, e.g., coenzyme\n             Q10).\n\n          -  Has lower body predominant symptoms.\n\n          -  Has supra-nuclear gaze palsy, CG sign, corticospinal track signs.\n\n        Inclusion Criteria (HC Subjects):\n\n          -  Male or female age 55 to 93 years at visit 1.\n\n          -  Ability to provide written informed consent in accordance with Good Clinical Practice\n             (GCP), International Conference on Harmonization (ICH), and local regulations.\n\n          -  Willing and able to comply with scheduled visits, required study procedures and\n             laboratory tests.\n\n        Exclusion Criteria (HC Subjects):\n\n          -  Family history of PD in first degree relatives.\n\n          -  Ashkenazi Jewish subject (defined as all 4 grandparents being Ashkenazi Jewish) will\n             be excluded because of the high likelihood of genetic forms of PD (LRRK2) and GBA),\n             unless these have been already excluded by genetic testing.\n\n          -  Has other serious neurological disorders (clinically significant stroke, brain tumor,\n             hydrocephalus, epilepsy, other neurodegenerative disorders, encephalitis, repeated\n             head trauma).\n\n          -  Has a history of cancer, autoimmune disorder, liver disease, or hematological\n             disorders within the past 5 years.\n\n          -  Has early severe autonomic involvement: symptomatic orthostatic hypotension or\n             urinary incontinence within one year of onset of disease symptom.\n\n          -  Current treatment with anticoagulants (e.g., Coumadin, heparin) that might preclude\n             safe completion of the lumbar puncture.\n\n          -  Condition that precludes the safe performance of routine lumbar puncture, such as\n             prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant\n             coagulopathy or thrombocytopenia.\n\n          -  Any other medical or psychiatric condition or lab abnormality, which in the opinion\n             of the investigator might preclude participation.\n\n          -  Use of investigational drugs or devices within 60 days prior to baseline (dietary\n             supplements taken outside of a clinical trial are not exclusionary, e.g., coenzyme\n             Q10).\n\n          -  MoCA score <26."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "93 Years", 
            "minimum_age": "55 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Parkinson's disease and healthy control subjects"
            }
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01705327", 
            "org_study_id": "BioFIND"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Parkinson's", 
            "Biomarkers", 
            "Neurodegenerative disorder"
        ], 
        "lastchanged_date": "December 17, 2013", 
        "location": [
            {
                "contact": {
                    "email": "jworrell@uab.edu", 
                    "last_name": "Jeff Worrell, RN, BSN, MPMM, CCRP", 
                    "phone": "205-996-4039"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35233"
                    }, 
                    "name": "University of Alabama at Birmingham"
                }, 
                "investigator": {
                    "last_name": "Amy Amara, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jyoung@neurology.bsd.uchicago.edu", 
                    "last_name": "Joan Young, CCRP", 
                    "phone": "773-834-1688"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois"
                    }, 
                    "name": "University of Chicago"
                }, 
                "investigator": {
                    "last_name": "Tao Xie, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jjaglin2@rush.edu", 
                    "last_name": "Jeana Jaglin", 
                    "phone": "312-942-5003"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois"
                    }, 
                    "name": "Rush University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Jennifer Goldman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Raszk001@umn.edu", 
                    "last_name": "Christa Raszkowski", 
                    "phone": "612-624-6778"
                }, 
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }, 
                    "name": "University of Minnesota"
                }, 
                "investigator": {
                    "last_name": "Paul Tuite, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ks2776@columbia.edu", 
                    "last_name": "Karina Sakanaka"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Columbia University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Roy Alcalay, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mao2026@med.cornell.edu", 
                    "last_name": "Mattson Ogg", 
                    "phone": "212-746-2474"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Cornell University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Claire Henchcliffe, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lenahan@ohsu.edu", 
                    "last_name": "Art Lenahan", 
                    "phone": "503-494-1382"
                }, 
                "contact_backup": {
                    "email": "portillo@ohsu.edu", 
                    "last_name": "Alicia Portillo", 
                    "phone": "503-494-1382"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "Oregon Health & Science University"
                }, 
                "investigator": {
                    "last_name": "Penelope Hogarth, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Fox Investigation for New Discovery of Biomarkers (BioFIND)", 
        "overall_contact": {
            "email": "movdis@columbia.edu", 
            "last_name": "Un Jung Kang, MD", 
            "phone": "212-305-1540"
        }, 
        "overall_official": [
            {
                "affiliation": "Rush University Medical Center", 
                "last_name": "Jennifer Goldman, MD, MS", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Columbia University", 
                "last_name": "Roy Alcalay, MD, MS", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Well Cornell Medical Center", 
                "last_name": "Claire Henchcliffe, MD, D. Phil", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Chicago", 
                "last_name": "Tao Xie, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Minnesota Medical Center", 
                "last_name": "Paul Tuite, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Chicago", 
                "last_name": "Un Jung Kang, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Clinical Trial Coordinating Center, University of Rochester", 
                "last_name": "Cindy Casaceli, MBA", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Oregon Health and Science University", 
                "last_name": "Penelope Hogarth, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Boston Medical Center", 
                "last_name": "Samuel A. Frank, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Alabama at Birmingham", 
                "last_name": "Amy Amara, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "No primary outcome measure", 
            "safety_issue": "No", 
            "time_frame": "Two years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01705327"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Michael J. Fox Foundation for Parkinson's Research", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute of Neurological Disorders and Stroke (NINDS)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Michael J. Fox Foundation for Parkinson's Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}